Disposable Technologies for Fill-Finish of Clinical-Trial Materials - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Disposable Technologies for Fill-Finish of Clinical-Trial Materials
The author examines the use and advantages of disposable technologies in the fill–finish of sterile pharmaceutical products and how these technologies can reduce costs and time in producing clinical-trial materials.


Pharmaceutical Technology
Volume 34, pp. s22-s25

Converting to a disposable system

Changing an existing reusable system to one that takes advantage of disposable technologies may not always seem to be an attractive option. The investment already made in existing equipment may restrict the implementation of disposable technologies in some facilities. However, even if it is considered to be impractical to invest in an entire disposable system, advantages can be gained from introducing elements of the disposable systems previously described. For example, increasing the use of disposable vessels (e.g., glass or plastic bottles and flexible bags) will potentially decrease turnaround times by reducing cleaning requirements.

Conclusions

Disposable technologies in the manufacture of clinical supplies of biopharmaceuticals offer the benefit of reducing cost, time, and risk. Some disposable technologies can be introduced into an existing facility quickly and at minimal cost. Savings can be achieved in the manufacturing process, and time efficiencies can be realized. By taking advantage of the removal of the requirement for cleaning verification when a fully disposable manufacturing equipment train is used, the time to get the product to the clinical trial can be reduced by as much as two months. For some companies, this improvement may be the most significant benefit of all.

References

1. A. Sinclair and M. Monge, BioProcess Intl. 3 (9), s51–s55 (2005).

2. M. Fuller and H. Pora, BioProcess Intl. 6 (10), 30–36 (2008).

3. G. Hodge, BioProcess Intl. 2 (5), 74–80 (2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here